
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LEQSELVI | Sun Pharmaceutical Industries | N-217900 RX | 2024-07-25 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| leqselvi | New Drug Application | 2025-07-17 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alopecia areata | EFO_0004192 | D000506 | L63 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | 1 | — | 2 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | — | — | — | 1 | — | 1 |
| T-cell lymphoma | D016399 | — | — | — | — | — | 1 | — | 1 |
| Syndrome | D013577 | — | — | — | — | — | 1 | — | 1 |
| Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | 5 | 5 | — | — | 9 |
| Alopecia | D000505 | — | L64 | — | 4 | 4 | — | — | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 1 | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | Deuruxolitinib |
| INN | deuruxolitinib |
| Description | Deuruxolitinib (CTP-543) is a Janus kinase inhibitor selective for JAK1 and JAK2. It is in development to treat alopecia areata. If approved the drug would compete with others with a similar mechanism of action developed by Eli Lilly and Pfizer.
|
| Classification | Small molecule |
| Drug class | deuterated compounds; tyrosine kinase inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | [2H]C1([2H])C([C@@H](CC#N)n2cc(-c3ncnc4[nH]ccc34)cn2)C([2H])([2H])C([2H])([2H])C1([2H])[2H] |
| PDB | — |
| CAS-ID | 1513883-39-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594381 |
| ChEBI ID | — |
| PubChem CID | 72704611 |
| DrugBank | DB18847 |
| UNII ID | 0CA0VSF91Y (ChemIDplus, GSRS) |
